Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Thermo Fisher Scientific to Divest Microbiology Business to Astorg for $1.075 Billion – Strategic Portfolio Optimization

Fineline Cube Apr 28, 2026
Company Deals

Aureka Biotechnologies Secures $35M Series A+ Financing to Advance AuraIDE Platform for Functional Antibody Design

Fineline Cube Apr 28, 2026
Company Deals

Hangzhou’s Adcoris Licenses First-in-Class 5T4-Targeting ADC ACR246 to U.S. Biotech K2 Therapeutics in Deal Worth Up to $730 Million

Fineline Cube Apr 27, 2026
Company Deals

Sino Biopharmaceutical’s Chia Tai Tianqing and Shanghai Reunion Partner to Commercialize Respacio Hydrogel for Cervical Cancer Radiotherapy Protection in China

Fineline Cube Apr 27, 2026
Company Deals

Beijing QL Biopharma Files HKEX IPO Prospectus with Diversified GLP-1 Portfolio Targeting Global Obesity and Metabolic Disease Markets

Fineline Cube Apr 27, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

Novartis Secures European Commission Approval for Rhapsido (remibrutinib) in Chronic Spontaneous Urticaria – Expanding Global BTK Inhibitor Franchise

Fineline Cube Apr 28, 2026
Company Drug

BeBetter Medicine Secures FDA Clearance for BEBT-701 Clinical Study – First-in-Class Dual-Target Therapy for Hypertension and High LDL-C

Fineline Cube Apr 28, 2026
Company Deals

Rici Healthcare to Acquire Unicorn II Holdings for RMB 180M

Fineline Cube Oct 24, 2022

China-based Rici Healthcare Holdings Limited (HKG: 1526), also known as Rich Healthcare, is set to...

Company

Roche Reports Q3 Sales Growth, Hit by COVID-19 Product Decline

Fineline Cube Oct 24, 2022

Swiss pharmaceutical giant Roche (SWX: ROG) released its Q3 2022 financial report last week, showing...

Company

Ambrx Biopharma Halts Development of HER2 ADC ARX788, Cuts Workforce

Fineline Cube Oct 21, 2022

US-based, China-owned biotech Ambrx Biopharma Inc. (NYSE: AMAM) has announced plans to end the development...

Drug R&D

Sinopharm’s Wuhan Institute Isolates Monkeypox Strains, Begins Vaccine Research

Fineline Cube Oct 21, 2022

China’s Wuhan Institute of Biological Products, a research affiliate of Sinopharm’s China National Biotech Group...

Company Deals

CATUG Biotechnology Partners with Duoning to Advance mRNA Industrialization

Fineline Cube Oct 21, 2022

China-based CATUG Biotechnology (Suzhou) Co., Ltd has entered into a partnership with compatriot firm Shanghai...

Policy / Regulatory

Fujian Procurement Center Announces VBP for Cardiac and Laparoscopic Medical Consumables

Fineline Cube Oct 21, 2022

The Fujian drug and device joint procurement center has released two separate notifications regarding the...

Policy / Regulatory

NMPA Releases 61st Batch of Reference Drugs for Generic Quality Consistency Evaluation

Fineline Cube Oct 21, 2022

The National Medical Products Administration (NMPA) has released the 61st batch of reference drugs for...

Company Drug

Betta Pharmaceuticals’ BPI-460372 Accepted for Clinical Trial Review by NMPA

Fineline Cube Oct 21, 2022

China’s Betta Pharmaceuticals (SHE: 300558) has announced that its clinical trial filing for the Category...

Company Drug

Frontier Biotechnologies Secures Approval for HIV Therapy Alfusid

Fineline Cube Oct 21, 2022

Nanjing-based Frontier Biotechnologies Inc. has announced that its supplementary market filing for Alfusid (albuvirtide), China’s...

Company Drug

Hengrui’s Camrelizumab and Akeso’s AK112 Set to Receive Breakthrough Designation in China

Fineline Cube Oct 21, 2022

The Center for Drug Evaluation (CDE) website indicates that China-based Jiangsu Hengrui Medicine Co., Ltd’s...

Company Drug

China Approves GSK’s Juluca for HIV-1 Infection

Fineline Cube Oct 21, 2022

The National Medical Products Administration (NMPA) has approved the market application for GlaxoSmithKline’s (GSK, NYSE:...

Company Drug

Hengrui Medicine Files for Dalpiciclib as Initial Therapy for Breast Cancer

Fineline Cube Oct 21, 2022

China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) has announced a supplementary market filing for...

Company Deals

HitGen Partners with C4X Discovery to Identify Novel Inflammatory Disease Treatments

Fineline Cube Oct 20, 2022

China-based HitGen Inc. (SHA: 688222) has announced a partnership with UK-headquartered C4X Discovery Holdings plc...

Company

Abbott Reports Q3 Sales Growth, Raises Full-Year EPS Guidance

Fineline Cube Oct 20, 2022

With the Q3 2022 reporting season underway, US-based medtech giant Abbott (NYSE: ABT) released its...

Company Policy / Regulatory

Shaanxi Releases Notice for Inter-Provincial Orthodontic Brackets VBP

Fineline Cube Oct 20, 2022

The Shaanxi Public Resources Trading Center has released the “Inter-provincial Alliance (regions, Corps) Orthodontic Brackets...

Company Drug

Hainan Poly Pharm’s Generic Ganciclovir Approved in Sweden for CMV Retinitis

Fineline Cube Oct 20, 2022

China-based Hainan Poly Pharm Co., Ltd (SHE: 300630) has announced receiving technical review approval from...

Company Drug

Bio-Thera’s BAT1806 Biosimilar Accepted for Review by European Medicine Agency

Fineline Cube Oct 20, 2022

China-based Bio-Thera Solutions Ltd (SHA: 688177) has announced that a Biologic License Application (BLA) for...

Company Deals

Kactus Biosystems Raises RMB 200M in Series B Financing for Protein and Enzyme Development

Fineline Cube Oct 20, 2022

Kactus Biosystems, a Shanghai-based firm specializing in target proteins and raw enzymes, has raised RMB...

Company Deals

Shandong Junxiu Biotechnology Secures RMB 45M in Series B Financing

Fineline Cube Oct 20, 2022

Shandong Junxiu Biotechnology Co., Ltd, a China-based maker of implantable regenerative medicine devices, has raised...

Company Drug

Brii Biosciences Reports Positive Phase I Results for HIV Treatments BRII-732 and BRII-778

Fineline Cube Oct 20, 2022

China-based Brii Biosciences Limited (HKG: 2137) has published the latest results of two Phase I...

Posts pagination

1 … 604 605 606 … 658

Recent updates

  • Thermo Fisher Scientific to Divest Microbiology Business to Astorg for $1.075 Billion – Strategic Portfolio Optimization
  • Novartis Secures European Commission Approval for Rhapsido (remibrutinib) in Chronic Spontaneous Urticaria – Expanding Global BTK Inhibitor Franchise
  • Eli Lilly to Acquire Ajax Therapeutics for Up to $2.3 Billion to Expand JAK Inhibitor Portfolio in Myeloproliferative Neoplasms
  • Aureka Biotechnologies Secures $35M Series A+ Financing to Advance AuraIDE Platform for Functional Antibody Design
  • BeBetter Medicine Secures FDA Clearance for BEBT-701 Clinical Study – First-in-Class Dual-Target Therapy for Hypertension and High LDL-C
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Thermo Fisher Scientific to Divest Microbiology Business to Astorg for $1.075 Billion – Strategic Portfolio Optimization

Company Drug

Novartis Secures European Commission Approval for Rhapsido (remibrutinib) in Chronic Spontaneous Urticaria – Expanding Global BTK Inhibitor Franchise

Others

Eli Lilly to Acquire Ajax Therapeutics for Up to $2.3 Billion to Expand JAK Inhibitor Portfolio in Myeloproliferative Neoplasms

Company Deals

Aureka Biotechnologies Secures $35M Series A+ Financing to Advance AuraIDE Platform for Functional Antibody Design

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.